Less than 10% of individuals eligible to benefit from weight-loss injections such as Wegovy can access them, caution the global health agency as it releases its inaugural advice on the medications.
Considering over a billion people worldwide currently obese, it is calling for increased and just availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The new guidelines acknowledges that obesity is a long-term condition that can be addressed with holistic and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key barriers to universal access to the jabs that can assist patients in reducing substantial weight, says the organization.
Skinny Jab Scarcity
Despite the present most optimistic scenario, the production of such drugs might only reach approximately 100 million people – under 10% of eligible patients, according to the health organization.
The recommendation encourages nations and manufacturers to widen access, by measures such as voluntary licensing.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Injections Function
GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and boost feelings of fullness so individuals reduce food intake.
Individuals typically begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Research points to patients may regain a significant portion a year later of discontinuing the drug, as their usual food cravings come back.
Being carrying excess weight increases your risk for contracting medical conditions, like diabetes, heart disease, brain attack, and certain malignancies.
Excess weight affects people in countries worldwide and was linked to millions of fatalities worldwide in 2024, as per the health agency.
